Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Breast Cancer Res Treat. 2019 May 22;177(1):29–40. doi: 10.1007/s10549-019-05279-9

Figure 2.

Figure 2.

Screening for buttressed analogs of DIM-C-pPhOH as NR4A1 antagonists. (A) SKBR3 cells were transfected with GAL4-NR4A1 and UAS-luc, treated with DIM-C-pPhOH and 9 buttressed analogs, and luciferase activity was determined as outlined in the Materials and Methods. (B) MDA-MB-231 and SKBR3 cells were treated with different concentrations of DIM-C-pPhOH (4-OH) for 24 h, and whole cell lysates were analyzed by western blots for downregulation of β1-integrin and TXNDC5. MDA-MBA-231 (C) and SKBR3 (D) cells were treated with 20 μM DIM-C-pPhOH (4-OH) and 5 μM concentrations of 9 buttressed analogs for 24 h, and whole cell lysates were analyzed by western blots for downregulation of β1-integrin and TXNDC5.